דוסיטקסל טבע ® 20 מ"ג / בקבוקון ו- 80 מ"ג/בקבוקון

Pays: Israël

Langue: hébreu

Source: Ministry of Health

Ingrédients actifs:

DOCETAXEL 27.73 MG / 1 ML

Disponible depuis:

ABIC MARKETING LTD

Code ATC:

L01CD02

forme pharmaceutique:

CONCENTRATE AND SOLVENT FOR SOLUTION FOR INFUSION

Mode d'administration:

I.V

Fabriqué par:

PHARMACHEMIE B.V., THE NETHERLANDS

Groupe thérapeutique:

DOCETAXEL

indications thérapeutiques:

Breast cancerDocetaxel Teva in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.Docetaxel Teva in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.Docetaxel Teva monotherapy is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.Docetaxel Teva in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease.Docetaxel Teva in combination with capecitabine is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have inclu

Date de l'autorisation:

2011-06-01